"An investment in knowledge pays the best interest."






Vaxil Bio Ltd. (VXL.V) has provided a further update to the company's press release dated Feb. 13, 2020, on the possible identification of a coronavirus (COVID-19) vaccine candidate.

The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil's proprietary VaxHitTM bioinformatics platform. The Vaccine Candidate's design is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine. Though significant, this is an early step in identifying a vaccine candidate which must then go through rigorous testing before approval by regulatory authorities.

During the next quarter, Vaxil plans to initiate non-GMP manufacturing. The non-GMP product will be made available for pre-clinical testing by those who express interest and qualify. In addition, Vaxil will explore partnerships and other possibilities to test the vaccine and if successful to bring to patients worldwide as expeditiously as possible

"This is a very early discovery and it is unlikely that there will be a prophylactic vaccine during this season, but we endeavor to have one for future use." said David Goren, Vaxil's Chairman and Chief Executive Officer.


Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA. The company continues to develop ImMucintm and is also developing a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation underway at a top US academic and research institution. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.